Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination

Tetsuro Kubota, Tomohisa Egawa, Yoshihide Otani, Toshiharu Furukawa, Yoshiro Saikawa, Masashi Yoshida, Masahiko Watanabe, Koichiro Kumai, Masaki Kitajima

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background: Because of the low chemosensitivity of gastric cancer to conventional antitumor agents, the role of adjuvant chemotherapy for patients with advanced gastric cancer is controversial. We have previously proposed the necessity to evaluate the appropriateness of particular adjuvant cancer chemotherapies in individual advanced gastric cancer patients using chemosensitivity testing. In the present study, we compared the chemosensitivity and clinical outcomes of patients with Stages III and IV gastric cancer. Patients and Methods: A total of 282 patients with advanced gastric cancer were analyzed retrospectively in terms of chemosensitivity as detected by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and survival outcome after surgery. Patients were split into groups according to Stage III or IV gastric cancer, then categorized into those that received surgery without chemotherapy (surgery-alone), and those that received adjuvant chemotherapy, for which all the evaluable cases were further divided into sensitive and resistant cases as determined by MTT assay. Results: For Stage III gastric cancer patients, the sensitive group had a more favorable survival outcome than the other two groups. For Stage IV gastric cancer patients, the sensitive groups, had a more favorable survival outcome than the other two groups, but only in the absence of peritoneal dissemination. Conclusion: Chemosensitivity testing, based on the MTT assay, was useful in evaluating the appropriate cancer chemotherapy for patients with Stages III/IV gastric cancer without peritoneal dissemination.

Original languageEnglish
Pages (from-to)583-587
Number of pages5
JournalAnticancer Research
Volume23
Issue number1 B
Publication statusPublished - 2003 Jan

Fingerprint

Adjuvant Chemotherapy
Stomach Neoplasms
Drug Therapy
Neoplasms
Survival
Antineoplastic Agents

Keywords

  • Adjuvant cancer chemotherapy
  • Gastric cancer
  • MTT assay
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination. / Kubota, Tetsuro; Egawa, Tomohisa; Otani, Yoshihide; Furukawa, Toshiharu; Saikawa, Yoshiro; Yoshida, Masashi; Watanabe, Masahiko; Kumai, Koichiro; Kitajima, Masaki.

In: Anticancer Research, Vol. 23, No. 1 B, 01.2003, p. 583-587.

Research output: Contribution to journalArticle

Kubota, Tetsuro ; Egawa, Tomohisa ; Otani, Yoshihide ; Furukawa, Toshiharu ; Saikawa, Yoshiro ; Yoshida, Masashi ; Watanabe, Masahiko ; Kumai, Koichiro ; Kitajima, Masaki. / Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination. In: Anticancer Research. 2003 ; Vol. 23, No. 1 B. pp. 583-587.
@article{f4ac8f7d859e4292b9603b5117d2d0de,
title = "Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination",
abstract = "Background: Because of the low chemosensitivity of gastric cancer to conventional antitumor agents, the role of adjuvant chemotherapy for patients with advanced gastric cancer is controversial. We have previously proposed the necessity to evaluate the appropriateness of particular adjuvant cancer chemotherapies in individual advanced gastric cancer patients using chemosensitivity testing. In the present study, we compared the chemosensitivity and clinical outcomes of patients with Stages III and IV gastric cancer. Patients and Methods: A total of 282 patients with advanced gastric cancer were analyzed retrospectively in terms of chemosensitivity as detected by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and survival outcome after surgery. Patients were split into groups according to Stage III or IV gastric cancer, then categorized into those that received surgery without chemotherapy (surgery-alone), and those that received adjuvant chemotherapy, for which all the evaluable cases were further divided into sensitive and resistant cases as determined by MTT assay. Results: For Stage III gastric cancer patients, the sensitive group had a more favorable survival outcome than the other two groups. For Stage IV gastric cancer patients, the sensitive groups, had a more favorable survival outcome than the other two groups, but only in the absence of peritoneal dissemination. Conclusion: Chemosensitivity testing, based on the MTT assay, was useful in evaluating the appropriate cancer chemotherapy for patients with Stages III/IV gastric cancer without peritoneal dissemination.",
keywords = "Adjuvant cancer chemotherapy, Gastric cancer, MTT assay, Survival",
author = "Tetsuro Kubota and Tomohisa Egawa and Yoshihide Otani and Toshiharu Furukawa and Yoshiro Saikawa and Masashi Yoshida and Masahiko Watanabe and Koichiro Kumai and Masaki Kitajima",
year = "2003",
month = "1",
language = "English",
volume = "23",
pages = "583--587",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - Cancer chemotherapy chemosensitivity testing is useful in evaluating the appropriate adjuvant cancer chemotherapy for stages III/IV gastric cancers without peritoneal dissemination

AU - Kubota, Tetsuro

AU - Egawa, Tomohisa

AU - Otani, Yoshihide

AU - Furukawa, Toshiharu

AU - Saikawa, Yoshiro

AU - Yoshida, Masashi

AU - Watanabe, Masahiko

AU - Kumai, Koichiro

AU - Kitajima, Masaki

PY - 2003/1

Y1 - 2003/1

N2 - Background: Because of the low chemosensitivity of gastric cancer to conventional antitumor agents, the role of adjuvant chemotherapy for patients with advanced gastric cancer is controversial. We have previously proposed the necessity to evaluate the appropriateness of particular adjuvant cancer chemotherapies in individual advanced gastric cancer patients using chemosensitivity testing. In the present study, we compared the chemosensitivity and clinical outcomes of patients with Stages III and IV gastric cancer. Patients and Methods: A total of 282 patients with advanced gastric cancer were analyzed retrospectively in terms of chemosensitivity as detected by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and survival outcome after surgery. Patients were split into groups according to Stage III or IV gastric cancer, then categorized into those that received surgery without chemotherapy (surgery-alone), and those that received adjuvant chemotherapy, for which all the evaluable cases were further divided into sensitive and resistant cases as determined by MTT assay. Results: For Stage III gastric cancer patients, the sensitive group had a more favorable survival outcome than the other two groups. For Stage IV gastric cancer patients, the sensitive groups, had a more favorable survival outcome than the other two groups, but only in the absence of peritoneal dissemination. Conclusion: Chemosensitivity testing, based on the MTT assay, was useful in evaluating the appropriate cancer chemotherapy for patients with Stages III/IV gastric cancer without peritoneal dissemination.

AB - Background: Because of the low chemosensitivity of gastric cancer to conventional antitumor agents, the role of adjuvant chemotherapy for patients with advanced gastric cancer is controversial. We have previously proposed the necessity to evaluate the appropriateness of particular adjuvant cancer chemotherapies in individual advanced gastric cancer patients using chemosensitivity testing. In the present study, we compared the chemosensitivity and clinical outcomes of patients with Stages III and IV gastric cancer. Patients and Methods: A total of 282 patients with advanced gastric cancer were analyzed retrospectively in terms of chemosensitivity as detected by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay and survival outcome after surgery. Patients were split into groups according to Stage III or IV gastric cancer, then categorized into those that received surgery without chemotherapy (surgery-alone), and those that received adjuvant chemotherapy, for which all the evaluable cases were further divided into sensitive and resistant cases as determined by MTT assay. Results: For Stage III gastric cancer patients, the sensitive group had a more favorable survival outcome than the other two groups. For Stage IV gastric cancer patients, the sensitive groups, had a more favorable survival outcome than the other two groups, but only in the absence of peritoneal dissemination. Conclusion: Chemosensitivity testing, based on the MTT assay, was useful in evaluating the appropriate cancer chemotherapy for patients with Stages III/IV gastric cancer without peritoneal dissemination.

KW - Adjuvant cancer chemotherapy

KW - Gastric cancer

KW - MTT assay

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=0037233739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037233739&partnerID=8YFLogxK

M3 - Article

VL - 23

SP - 583

EP - 587

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -